(Q36470388)

14 August 2017

1 reference

title

A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy (English)

1 reference

14 August 2017

0 references

anti-retroviral agent

0 references

1 reference

Justin Stebbing

1

1 reference

14 August 2017

Adam Sanitt

2

1 reference

14 August 2017

Mark Nelson

3

1 reference

14 August 2017

Tom Powles

4

1 reference

14 August 2017

Brian Gazzard

5

1 reference

14 August 2017

Mark Bower

6

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

367

1 reference

14 August 2017

issue

9521

1 reference

14 August 2017

page(s)

1495-1502

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Disseminated Kaposi's sarcoma in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Perspective on Kaposi's sarcoma: facts, concepts, and conjectures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

How does HAART lead to the resolution of Kaposi's sarcoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Kaposi's sarcoma as a model for cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma (KS): implications for the design of therapeutic trials in patients with advanced symptomatic KS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Survival analysis in clinical trials: past developments and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Regression modelling strategies for improved prognostic prediction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

A strategy for modelling the effect of a continuous covariate in medicine and epidemiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Estimating the Dimension of a Model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Assessing the generalizability of prognostic information

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Quantification of Kaposi's Sarcoma-Associated Herpesvirus in Blood, Oral Mucosa, and Saliva in Patients with Kaposi's Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968649-2

7 January 2021

10.1016/S0140-6736(06)68649-2

Identifiers

DOI

1 reference

14 August 2017

1 reference